Four AI Semiconductor Stocks Reach High Exhaustion Readings
Four semiconductor stocks posted scores above 87 on a technical model that measures how far prices have moved from normal ranges. The model combines several indicators and has historically preceded pullbacks when readings exceed 75.
insidermonkey.comFour AI-related semiconductor stocks reached exhaustion scores above 87 on a composite technical model developed by Jordi Visser. , and Intel Corp. These were the four highest readings among more than 100 names tracked in the AI Macro Nexus universe.
The exhaustion score ranges from 1 to 100 and incorporates RSI on 14-day and 5-day timeframes, Williams %R, a stock's 20-day position relative to its range, and 20-day and 50-day extension from average true range. A score above 75 indicates a stock is stretched across most of these measures at once. The reading quantifies distance from normal trading ranges but does not forecast reversal timing.
Research at 22V Research, said he sold his entire Micron position after the reading appeared. "Definitely out of all of Micron," he said in his latest weekly video. The model highlights a gap between earnings fundamentals and the speed at which prices have risen to current levels.
Transparency
Story details
Related Stories
Frontier AI Labs Report Rapid Capability Gains and AI-Written Code; Anthropic Calls for Coordinated Slowdown
Anthropic called for a slowdown or pause among labs developing the most advanced AI systems. The request appeared in a Thursday blog post from its research institute.
Ars TechnicaBumblebees Demonstrate Spontaneous Object Manipulation in Controlled Experiments
A study published in Science shows bumblebees can spontaneously use a ball as a ladder to reach a flower, marking the first demonstration of this type of problem-solving in an insect.
EuronewsSmall Phase 1 Safety Trial Tests First AI-Designed Coronavirus Vaccine Candidate
A Phase 1 safety study of an AI-designed protein vaccine against multiple coronaviruses enrolled 39 volunteers and reported no significant safety issues. A Phase 2 trial is now planned.